

UCLA

UCLA Previously Published Works

Title

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Bloo...

Permalink

<https://escholarship.org/uc/item/9dn7j9rp>

Journal

Haematologica, 106(8)

ISSN

0390-6078

Authors

Lazaryan, Aleksandr

Dolan, Michelle

Zhang, Mei-Jie

et al.

Publication Date

2021-08-01

DOI

10.3324/haematol.2021.279046

Peer reviewed

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Aleksandr Lazaryan,¹ Michelle Dolan,² Mei-Jie Zhang,^{3,4} Hai-Lin Wang,³ Mohamed A. Kharfan-Dabaja,⁵ David I. Marks,⁶ Nelli Bejanyan,⁷ Edward Copelan,⁸ Navneet S. Majhail,⁹ Edmund K. Waller,¹⁰ Nelson Chao,¹¹ Tim Prestidge,¹² Taiga Nishihori,¹³ Partow Kebriaei,¹⁴ Yoshihiro Inamoto,¹⁵ Betty Hamilton,¹⁶ Shahrukh K. Hashmi,^{17,18} Rammurti T. Kamble,¹⁹ Ulrike Bacher,²⁰ Gerhard C. Hildebrandt,²¹ Patrick J. Stiff,²² Joseph McGuirk,²³ Ibrahim Aldoss,²⁴ Amer M. Beitinjaneh,²⁵ Lori Muffly,²⁶ Ravi Vij,²⁷ Richard F. Olsson,^{28,29} Michael Byrne,³⁰ Kirk R. Schultz,³¹ Mahmoud Aljurf,¹⁸ Matthew Seftel,³² Mary Lynn Savoie,³³ Bipin N. Savani,³⁴ Leo F. Verdonck,³⁵ Mitchell S. Cairo,³⁶ Nasheed Hossain,³⁷ Vijaya Raj Bhatt,³⁸ Haydar A. Frangoul,³⁹ Hisham Abdel-Azim,⁴⁰ Monzer Al Malki,²⁴ Reinhold Munker,⁴¹ David Rizzieri,⁴² Nandita Khera,⁴³ Ryotaro Nakamura,⁴⁴ Olle Ringdén,⁴⁵ Marjolein van der Poel,⁴⁶ Hemant S. Murthy,⁴⁷ Hongtao Liu,⁴⁸ Shahram Mori,⁴⁹ Satiro De Oliveira,⁵⁰ Javier Bolaños-Meade,⁵¹ Mahmoud Elsayy,⁵² Pere Barba,⁵³ Sunita Nathan,⁵⁴ Bijou George,⁵⁵ Attaphol Pawarode,⁵⁶ Michael Grunwald,⁵⁷ Vaibhav Agrawal,⁵⁸ Youjin Wang,⁵⁹ Amer Assal,⁶⁰ Paul Castillo Caro,⁶¹ Yachiyo Kuwatsuka,⁶² Sachiko Seo,⁶³ Celalettin Ustun,⁶⁴ Ioannis Politikos,⁶⁵ Hillard M. Lazarus,⁶⁶ Wael Saber,³ Brenda M. Sandmaier,⁶⁷ Marcos De Lima,⁶⁸ Mark Litzow,⁶⁹ Veronika Bachanova,⁷⁰ and Daniel Weisdorf,⁷¹ Acute Leukemia Committee of the CIBMTR³

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; ²University of Minnesota Medical Center, Minneapolis, MN, USA;

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA;

⁵Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; ⁶Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK; ⁷Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA; ⁸Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC, USA; ⁹Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; ¹⁰Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; ¹¹Division of Cell Therapy and Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA; ¹²Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand; ¹³Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; ¹⁴Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, TX, USA; ¹⁵Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; ¹⁶Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; ¹⁷Department of Internal Medicine, Mayo Clinic, MN, USA; ¹⁸Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; ¹⁹Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; ²⁰Department of Hematology, Inselspital, Bern University Hospital, Switzerland; ²¹Markey Cancer Center, University of Kentucky, Lexington, KY, USA; ²²Loyola University Medical Center, Maywood, IL, USA; ²³University of Kansas Medical Center, Westwood, KS, USA; ²⁴City of Hope Comprehensive Cancer Center, Duarte, CA, USA; ²⁵University of Miami, Miami, FL, USA; ²⁶Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, USA; ²⁷Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA; ²⁸Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; ²⁹Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden;

³⁰Vanderbilt University Medical Center, Nashville, TN, USA; ³¹Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; ³²Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada; ³³Tom Baker Cancer Centre, Calgary, Alberta, Canada; ³⁴Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; ³⁵Department of Hematology/Oncology, Isala Clinic, Zwolle, the Netherlands; ³⁶Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY, USA; ³⁷Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; ³⁸The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; ³⁹The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN, USA; ⁴⁰Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA;

⁴¹Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA; ⁴²Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA; ⁴³Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA; ⁴⁴Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA;

⁴⁵Translational Cell Therapy Group, CLINTEC (Clinical Science, Intervention and Technology), Karolinska Institutet, Stockholm Sweden; ⁴⁶Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; ⁴⁷Mayo Clinic Florida, Jacksonville, FL, USA; ⁴⁸University of Chicago Medicine, Chicago, IL, USA; ⁴⁹Blood & Marrow Transplant Center, Florida Hospital Medical Group, Orlando, FL, USA; ⁵⁰UCLA Medical Center, Los Angeles, CA, USA; ⁵¹The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; ⁵²QE II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada; ⁵³Hospital Vall d'Hebron, Barcelona, Spain; ⁵⁴Rush University Medical Center, Chicago, IL, USA; ⁵⁵Christian Medical College, Vellore, India; ⁵⁶Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA; ⁵⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; ⁵⁸Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN, USA; ⁵⁹National Cancer Institute (NCI), Rockville, MD, USA; ⁶⁰New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; ⁶¹UF Health Shands Children's Hospital, Gainesville, FL, USA; ⁶²Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; ⁶³Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan; ⁶⁴Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL, USA; ⁶⁵Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁶⁶Case Western Reserve University, Cleveland, OH, USA; ⁶⁷Division of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;

⁶⁸Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA; ⁶⁹Division of

Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN, USA; ⁷⁰Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA and ⁷¹Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.

Published in *Haematologica* 2020;105(5):1329-1338

doi:10.3324/haematol.2021.279046

©2021 Ferrata Storti Foundation

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors' part as these grants did not support the research in this publication.

An incorrect version of “acknowledgments” appeared in the May 2020 issue on page 1337.

Acknowledgments

The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grant U24CA233032 from the NCI; grants OT3HL147741, R21HL140314 and U01HL128568 from the NHLBI; a contract HSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children's Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children's Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Pharmacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members.

The correct version of “acknowledgments” is published on this page.

Acknowledgments

The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grants R21HL140314 and U01HL128568 from the NHLBI; a contract HSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children's Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children's Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Pharmacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members.